Study title: Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David. Division of Metabolism and Molecular Pediatrics, University Children's Hospital, Zurich, Switzerland.. Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy. American journal of human genetics, {Am-J-Hum-Genet}, Nov 2004 (epub: 09 Sep 2004), vol. 75, no. 5, p. 790-800, ISSN: 0002-9297.Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David. Division of Metabolism and Mo...
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nutritional and Metabolic Diseases [C18] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BIOTIN | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |